

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

SU-DHL-10

RRID:CVCL_1889

Type: Cell Line

Proper Citation

RRID:CVCL_1889

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1889

Proper Citation: RRID:CVCL_1889

Description: Cell line SU-DHL-10 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:83902](#), [PMID:177185](#), [PMID:214220](#), [PMID:371794](#), [PMID:1465024](#), [PMID:3881165](#), [PMID:8547074](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:19278952](#), [PMID:19358282](#), [PMID:20054396](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:23257783](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-10

Synonyms: Su-DHL-10, SUDHL10, Sudhl10, SUDHL-10, SuDHL 10, Stanford University-Diffuse Histiocytic Lymphoma-10, DHL10

Cross References: CLO:CLO_0037059, EFO:EFO_0002354, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-2963, BioGRID_ORCS_Cell_line:1024, BioSample:SAMN03471872, BioSample:SAMN10988471, cancercellines:CVCL_1889, CCTCC:GDC0217, Cell_Model_Passport:SIDM00389, ChEMBL-Cells:ChEMBL4483178, ChEMBL-Targets:ChEMBL4483268, Cosmic:850207, Cosmic:1067460, Cosmic:1079257, Cosmic:1517644, Cosmic:1541914, Cosmic:1636685, Cosmic:2276343, Cosmic:2361377, Cosmic-CLP:1331033, DepMap:ACH-000271, DSMZ:ACC-576, DSMZCellDive:ACC-576, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1331033, GEO:GSM380143, GEO:GSM552468, GEO:GSM887651, GEO:GSM888743, GEO:GSM1035312, GEO:GSM1059808, GEO:GSM1374904, GEO:GSM1670483, IARC_TP53:28255, IGRhCellID:SUDHL10, LiGeA:CCL_214, LINCS_LDP:LCL-1134, PharmacDB:SUDHL10_1500_2019, PRIDE:PXD030304, Progenetix:CVCL_1889, PubChem_Cell_line:CVCL_1889, Wikidata:Q54970706

ID: CVCL_1889

Record Creation Time: 20220427T221611+0000

Record Last Update: 20260920T005901+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-10.

No alerts have been found for SU-DHL-10.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy.

Cancer research.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Schwarzer A, et al. (2023) Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1. *Molecular cancer therapeutics*, 22(11), 1290.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Roberto MP, et al. (2021) Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. *Immunity*, 54(8), 1807.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Park S, et al. (2020) Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. *Cancers*, 12(9).

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. *Cell chemical biology*, 27(5), 538.